iOncologi
Gainsville, US · Delaware corporation · 4 employees on LinkedIn
iOncologi develops immunotherapy platforms designed to treat cancer by priming the immune system to attack tumors and overcoming immune resistance. The company's proprietary technologies target solid tumors and refractory cancers through personalized immune conditioning and cell-based approaches.
Founders & leadership
DE
Dr. Edgardo Rodriguez-LebronCo-founder, President, and CEO
DD
Dr. Duane MitchellCo-founder and Chairman
DC
Dr. Catherine FloresCo-founder
ER
Edgardo RodriguezExecutive
MM
Michelle MitchellExecutive
DM
Duane MitchellNamed on SEC filing
Board
PK
Peter KashBoard director
CF
Catherine FloresBoard director
Reported raises · per SEC filings
Form D private placements$3.3M disclosed across 2 rounds · 2025
▶$250KraisedMay 2025 · 3 investors · BiotechnologyRule 506(b)
▶$250KraisedMay 2025 · 3 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Paolo FundaroDirector
- Peter KashDirector
- Duane MitchellDirector
- Mona FloresDirector
- Edgardo Rodriguez-LebronExecutive Officer, Director
- Offering amount
- $12M
- Amount sold
- $250K
- First sale
- May 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$3MraisedMar 2025 · 17 investors · BiotechnologyRule 506(b)
▶$3MraisedMar 2025 · 17 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Edgardo RodriguezExecutive Officer, Director
- Michelle MitchellExecutive Officer, Director
- Peter KashDirector
- Catherine FloresDirector
- Duane MitchellExecutive Officer, Director
- Offering amount
- $3M
- Amount sold
- $3M
- Sales commissions
- $142.7K
- Placement agents
- ARCADIA SECURITIES, LLC (Brookline Capital Markets)
- First sale
- Feb 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 5
by search overlap
Immuneering7 shared keywordsImmuneering develops Deep Cyclic Inhibitors, a class of oncology medicines designed to pulse dosing faster than cancer's adaptive mechanisms to limit resistance and reduce side effects. The company targets more durable tumor control and improved tolerability for cancer patients.
Inimmune6 shared keywordsInimmune is a clinical-stage biotech company developing immunotherapies for allergy, cancer, infectious, and autoimmune diseases. The company combines immunology and vaccine expertise to advance its clinical and pre-clinical pipeline.
Immune-Onc Therapeutics6 shared keywordsImmune Onc is a biotechnology company developing medicines to treat patients with hard-to-treat cancers and autoimmune diseases, with expertise in translational medicine and clinical development.
Immunocore6 shared keywordsImmunocore is a biotechnology company developing T cell receptor (TCR) based immunomodulating therapies for patients with cancer, infectious diseases, and autoimmune diseases.
Oncimmune6 shared keywordsOncimmune is a biomarker discovery and diagnostics company specializing in proteomics and bioinformatics technologies for autoimmunity, cancer research, and clinical drug development. The company serves pharmaceutical, biotech, and academic partners by developing diagnostic tools and biomarkers for various phases of clinical development.
Companies competing with iOncologi for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does iOncologi do?
- iOncologi develops immunotherapy platforms designed to treat cancer by priming the immune system to attack tumors and overcoming immune resistance. The company's proprietary technologies target solid tumors and refractory cancers through personalized immune conditioning and cell-based approaches.
- Who founded iOncologi?
- iOncologi was founded by Dr. Edgardo Rodriguez-Lebron, Dr. Duane Mitchell, Dr. Catherine Flores.
- How much funding has iOncologi raised?
- iOncologi has disclosed $3.3M raised across 2 rounds.
- Where is iOncologi headquartered?
- iOncologi is headquartered in Gainsville, US.